Follow-on biologics: A new play for big pharma: Healthcare 2010

Yale Journal of Biology and Medicine

Volumn 83, Issue 2, 2010, Pages 97-100

  Evans, Ian ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; GENERIC DRUG; BIOLOGICAL PRODUCT;

ARTICLE; COST CONTROL; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; MEDICOLEGAL ASPECT; RHEUMATOID ARTHRITIS; DRUG DESIGN; UNITED STATES;

BIOLOGICAL PRODUCTS; DRUG DESIGN; DRUG INDUSTRY; UNITED STATES;

EID: 77957329157     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Farkas C, van Biesen T. The Real Reason Big Pharma Mergers AreWise. Forbes Magazine. 26 June 2009. Available from: http://www.forbes.com/2009/06/26/bigpharma-mergers-leadership-governanceacquisitions.html.
2. IMS Health Midas. Top 15 Global Products, 2009, TotalAuditedMarkets. December 2009. Available from: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Static-File/Top_Line_Data/Top%2015%20Global%20Products_2009.pdf.
3. Amgen. Press Release. 17 Dec 2001.Available from: http://www.amgen.com/pdfs/immunex/pressRelease011217.pdf.
4. Bethencourt V. Merck joins the biotech game. NatBiotech. 2009;27(2):104.
5. Rockoff J, Loftus P. Pfizer Pushes on New Biotech Drugs. Wall Street Journal. 28 April 2010.Available from: http://online.wsj.com/article/SB10001424052748704464704575208580328253618.html.
6. Kambhammettu S. The European Biosimilars Market: Trends and Key Success Factors. Scicast Special Reports. 27 Oct 2008. Available from: http://scicasts.com/specialreports/20-biopharmaceuticals/2152-the-european-biosimilars-market-trends-and-keysuccess-factors.
7. Emerging Health Care Issues: Follow-on Biologic Drug Competition Federal Trade Commission Report. June 2009. Available from: http://www.ftc.gov/os/2009/06/P083901biologicsreport.pdf.